The approach collects multiple types of imaging and sequencing data from the same cells, leading to new insights into mouse liver biology.

Whitehead Institute and CSAIL researchers created a machine-learning model to predict and generate protein localization, with implications for understanding and remedying disease.

Chronic diseases like diabetes are prevalent, costly, and challenging to treat. A common denominator driving them may be a promising new therapeutic target.

A new gene-silencing tool shows promise as a future therapy against prion diseases and paves the way for new approaches to treating disease.

Whitehead Institute Member Jonathan Weissman and collaborators developed a tool to reconstruct human cell family trees, revealing how blood cell production changes in old age.

Team-based targeted projects, multi-mentor fellowships ensure that scientists studying social cognition, behavior, and autism integrate multiple perspectives and approaches to pressing questions.

Whitehead Institute researchers find many transcription factors bind RNA, which fine-tunes their regulation of gene expression, suggesting new therapeutic opportunities.

A new approach for identifying significant differences in gene use between closely-related species provides insights into human evolution.

Matt Shoulders will lead an interdisciplinary team to improve RuBisCO — the photosynthesis enzyme thought to be the holy grail for improving agricultural yield.

On March 10 the FDA approved Trofinetide, a drug based on the protein IGF-1. The MIT professor's original research showing that IGF-1 could treat Rett was published in 2009.